In blast crisis of CML and in de novo Ph+ ALL, BCR-ABL retains sensitivity to imatinib, but additional genetic abnormalities conferring drug resistance are common. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.